1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (6438)
  2. Meeting Abstract (5172)
  3. Review (332)
  4. Book Section (310)
  5. Editorial (92)
  6. Research Letter (73)
  7. Guidelines (52)
  8. Correspondence (47)
  9. Conference Paper (38)
  10. Miscellaneous (37)
  11. Book Whole (24)
Groups
  1. Department of Pathology and Laboratory Medicine (12615)
  2. GSK Faculty (4773)
  3. Department of Medicine (4722)
  4. Surgery (3639)
  5. Solid Tumor Oncology Division (3422)
  6. Human Oncology and Pathogenesis Program (3037)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Victor Reuter (1228)
  3. Cristina Antonescu (895)
  4. Michael Berger (765)
  5. William Travis (743)
  6. Jinru Shia (719)

More People

Years
  1. 2025 (307)
  2. 2024 (719)
  3. 2023 (766)
  4. 2022 (841)
  5. 2021 (677)
  6. 2020 (787)

More Years

Publications
  1. Laboratory Investigation (1448)
  2. Modern Pathology (1440)
  3. Journal of Clinical Oncology (863)
  4. American Journal of Surgical Pathology (429)
  5. Cancer Research (426)
  6. Blood (349)

More Publications

Publishers
  1. Nature Publishing Group (1939)
  2. Nature Research (1457)
  3. Elsevier Inc. (1139)
  4. American Society of Clinical Oncology (955)
  5. American Association for Cancer Research (923)
  6. Lippincott Williams & Wilkins (896)

More Publishers

Results (12615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers
    Meeting Abstract

    Somwar, R.; Smith, R.; Hayashi, T.; Ishizawa, K.; Charen, A. S.; Khodos, I.; Mattar, M.; He, J.; Balasubramanian, S.; Stephens, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)
    Meeting Abstract

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients
    Meeting Abstract

    Segal, N. H.; Kemeny, N. E.; Cercek, A.; Reidy, D. L.; Raasch, P. J.; Warren, P.; Hrabovsky, A. E.; Campbell, N.; Shia, J.; Goodman, K. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?
    Meeting Abstract

    Sahin, I. H.; Turkekul, M.; Capanu, M.; Askan, G.; McMahon, B.; Yu, K. H.; Lowery, M. A.; Basturk, O.; Iacobuzio-Donahue, C.; O'Reilly, E. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Association of outcomes and co-occuring genomic alterations in patients with KRAS-mutant non-small cell lung cancer
    Meeting Abstract

    Riely, G.; Jordan, E.; Kim, H. R.; Yu, H. A.; Berger, M. F.; Solit, D. B.; Kris, M. G.; Ni, A.; Arcila, M. E.; Ladanyi, M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status
    Meeting Abstract

    Razavi, P.; Cecchi, F.; Ross, D. S.; Middha, S.; Zehir, A.; Arcila, M. E.; Hembrough, T. A.; Berger, M. F.; Scaltriti, M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT
    Meeting Abstract

    Raj, N. P.; Soumerai, T.; Valentino, E.; Hechtman, J. F.; Berger, M. F.; Reidy, D. L.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Waqar, S. N.; Dowlati, A.; Hann, C. L.; Chiappori, A.; Owonikoko, T. K.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Differences in somatic DNA damage repair (DDR) gene alterations between primary and secondary muscle invasive bladder cancer (MIBC)
    Meeting Abstract

    Pietzak, E. J.; Bagrodia, A.; Li, Q.; Al-Ahmadie, H.; Herr, H. W.; Funt, S.; Barron, D.; Zehir, A.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC)
    Meeting Abstract

    Patel, V. G.; McBride, R. B.; Lorduy, A. C.; Castillo-Martin, M.; Cha, E. K.; Berger, M. F.; Wang, L.; Oh, W. K.; Zhu, J.; Cordon-Cardo, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save